ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO404

Urinary Clusterin Associates With Height Corrected Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease

Session Information

Category: Genetic Diseases of the Kidneys

  • 1101 Genetic Diseases of the Kidneys: Cystic

Authors

  • Gitomer, Berenice Y., University of Colorado, Denver, Colorado, United States
  • Wang, Wei, University of Colorado, Denver, Colorado, United States
  • Ringling, Jessica, University of Colorado, Denver, Colorado, United States
  • Nowak, Kristen L., University of Colorado, Denver, Colorado, United States
  • Jovanovich, Anna, University of Colorado, Denver, Colorado, United States
  • You, Zhiying, University of Colorado, Denver, Colorado, United States
  • Hopp, Katharina, University of Colorado, Denver, Colorado, United States
  • Chonchol, Michel, University of Colorado, Denver, Colorado, United States
Background

Clusterin, also known as apolipoprotein J (APoJ), is a secreted glycoprotein expressed in various tissues and body fluids. Kidney and urinary clusterin levels (uclusterin) are related to renal tubular injury and are induced in acute kidney injury, diabetic kidney diseases as well as animal and human cystic diseases including ADPKD. We have previously shown that urinary Kim-1 a kidney injury biomarker is associated with estimated glomerular filtration rate (eGFR) and height corrected total kidney volume (HtTKV) in different stages of ADPKD. Thus, we hypothesized that uclusterin may represent a similar biomarker of HtTKV or eGFR in ADPKD patients.

Methods

Baseline urinary clusterin/Cr levels were measured in ADPKD participants from our clinical trial examining the effect of pravastatin on ADPKD progression. Eighty patients with baseline estimated glomerular filtration rate (eGFR) ≥45ml/min/1.73m2 (CKD Epi equation) who completed the study were included in this cross-sectional study. Clusterin levels in a spot urine sample collected at baseline were measured by ELISA (R&D systems) and normalized by urine creatinine. The association of baseline urinary clusterin/Cr with Ln transformed height corrected total kidney volume (ln-HtTKV) or eGFR were evaluated using correlation analysis and linear regression with covariate adjustment.

Results

Participants were 42 ±11 years old at the baseline. Forty-eight (60%) were female. Mean BMI was 26.6±5.7kg/m2 and systolic blood pressure (SBP) was 123±11mmHg. Baseline eGFR was 90±19 ml/min/1.73 m2 and HtTKV 761±396 ml/m. Baseline urinary clusterin/Cr was 0.22±0.14 x 10-3. Urinary clusterin/Cr level correlated with baseline In-HtTKV 0.31 (β 1.13, 95% CI 0.34, 1.92) p=0.006. The association remained significant even after adjustment for sex age, BMI and SBP. However, there was no association between uClusterin/Cr with eGFR.

Conclusion

Urinary Clusterin/Cr is associated with HtTKV in ADPKD. It might serve as an early biomarker in monitoring disease progression in ADPKD.

Funding

  • Other U.S. Government Support